Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch

TipRanks12-13

Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491327226?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JAkd0u.p7aqm9cNkwT3ICg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91","is_english":true,"pubTime":"2024-12-13 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491327226","market":"us","top_or_hot":-1,"title":"Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch","media":"TipRanks","content":"<div>\n<p>Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent...</p>\n\n<a href=\"https://finance.yahoo.com/news/jazz-upgraded-overweight-morgan-stanley-130054146.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJazz upgraded to Overweight at Morgan Stanley after Ziihera launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/jazz-upgraded-overweight-morgan-stanley-130054146.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent...</p>\n\n<a href=\"https://finance.yahoo.com/news/jazz-upgraded-overweight-morgan-stanley-130054146.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"https://finance.yahoo.com/news/jazz-upgraded-overweight-morgan-stanley-130054146.html","article_id":"2491327226","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JAkd0u.p7aqm9cNkwT3ICg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c7cc0ee97ba22ee31ce2f6fcf51d1f91"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-upgraded-overweight-morgan-stanley-130054146.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2491327226","pubTimestamp":1734094854,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Morgan Stanley upgraded Jazz Pharmaceuticals  to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent approval. Ziihera is now available to prescribers in the U.S. at a wholesale acquisition cost price of about $35,500 for a 28-day cycle, the analyst noted. With the launch of Ziihera in biliary tract cancer and Phase 3 data in gastroesophageal adenocarcinoma due in Q2 of 2025, the firm believes the company is “well-positioned for shares to appreciate in 2025,” the analyst tells investors.Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. ALX Oncology announces results from Phase 1b/2 trial. Jazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines. Roche announces FDA approval of label expansion into biliary tract cancer. FDA grants accelerated approval to Jazz Pharmaceuti","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"Ziihera推出后，摩根士丹利将Jazz升级为跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":0.9},"content_text":"Morgan Stanley upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $175, up from $140, after the company hosted an investor call on Ziihera following the recent approval. Ziihera is now available to prescribers in the U.S. at a wholesale acquisition cost price of about $35,500 for a 28-day cycle, the analyst noted. With the launch of Ziihera in biliary tract cancer and Phase 3 data in gastroesophageal adenocarcinoma due in Q2 of 2025, the firm believes the company is “well-positioned for shares to appreciate in 2025,” the analyst tells investors.\n\nPick the best stocks and maximize your portfolio:\n\nDiscover top-rated stocks from highly ranked analysts with Analyst Top Stocks!\nEasily identify outperforming stocks and invest smarter with Top Smart Score Stocks\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee the top stocks recommended by analysts >>\n\n\nRead More on JAZZ:\n\nALX Oncology announces results from Phase 1b/2 trial\nJazz Pharmaceuticals’ Ziihera now included in updated NCCN guidelines\nJazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio\nRoche announces FDA approval of label expansion into biliary tract cancer\nFDA grants accelerated approval to Jazz Pharmaceuticals’ Ziihera","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491327226"}